Droxidopa NEW
| Price | $73 | $98 | $159 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Droxidopa | CAS No.: 23651-95-8 |
| Purity: 97.27% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Droxidopa |
| Description | Droxidopa (L-DOPS) is an effective orally active norepinephrine precursor capable of crossing the blood-brain barrier. It can increase standing blood pressure, improve symptoms of orthostatic hypotension, and enhance standing ability. Droxidopa is commonly used in studies of neurogenic orthostatic hypotension (nOH) and alternative treatments for attention-deficit/hyperactivity disorder (ADHD). |
| In vivo | Droxidopa is administered orally and is absorbed and converted to norepinephrine by the enzyme dopa decarboxylase, which, together with endogenous norepinephrine, increases neurotransmitter levels.Droxidopa also crosses the blood-brain barrier (BBB) and is converted to norepinephrine and epinephrine in the brain. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.14 mg/mL (10.04 mM), Sonication is recommended. H2O : 1.25 mM, Sonication is recommended. |
| Keywords | SM-5688 | SM 5688 | orally active | neurogenic orthostatic hypotension | Inhibitor | inhibit | Droxidopa | blood pressure | Beta Receptor | AdrenergicReceptor | Adrenergic Receptor | ADHD |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-05 | ||
| $19.00 |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-12 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-01 | ||
| $8.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2025-09-25 | |
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY